Trials soon ready
Clinical trials expected to report results within the next 3 months, ranked by potential. Each trial shows its estimated finish date — explained in plain language.
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Results expected Nov 2026 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New antibody drug aims to tame ulcerative colitis in major trial
Disease control OngoingThe purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achiev…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). …
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
AbbVie · ABBV NYSE Trade on eToro (ad)Reward if it works ModerateAn incremental result rather than a breakthrough.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
New drug duo aims to stall advanced breast cancer
Disease control OngoingThe study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control OngoingIn this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a heal…
Results expected Sep 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
Bayer AG · BAYN XETRAReward if it works ModerateAn incremental result rather than a breakthrough.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
New drug cocktail aims to stall lung cancer progression
Disease control OngoingThis is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unr…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for EGFR lung cancer: Dato-DXd combo tested in phase 3 trial
Disease control Recruiting nowThis study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vess…
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
AbbVie · ABBV NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
⭐️ VACCINE ⭐️ Recruiting nowThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 23, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
Kidney cancer combo aims to stop recurrence after surgery
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary st…
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New obesity drug retatrutide takes on tirzepatide in major trial
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
Eli Lilly and Company · LLY NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New pill aims to cut stroke risk without the bleeding worry
Disease control OngoingThe purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
Johnson & Johnson · JNJ NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for Hard-to-Treat breast cancer: Head-to-Head drug trial launches
Disease control OngoingThis is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (H…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
Roche Holding AG · RHHBY OTCReward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to a broker we have a commercial relationship with, and we may earn a commission if you open an account. This never affects which trials are listed or how they are ranked.